Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Elise C KohnE Reed

Abstract

Cytostatic agents targeted against angiogenesis and tumor cell invasive potential form a new class of investigational drugs. Orally administered carboxyamidotriazole (CAI) (NSC609974) is both antiangiogenic and antimetastatic. An encapsulated micronized powder formulation has been developed to optimize CAI administration. A phase I dose escalation trial with pharmacokinetic analysis has been performed. Twenty-one patients with refractory solid tumors and good end organ function and performance status were enrolled onto the study. Patients received a test dose followed 1 week later by daily administration of CAI in the encapsulated micronized formulation at doses of 100 to 350 mg/m2. Patients remained on CAI until disease progression or dose-limiting toxicity. Plasma samples were taken to characterize the pharmacokinetic parameters of this formulation of CAI. All patients were assessable for toxicity and 18 were assessable for pharmacokinetics and response analysis. Grade 1 and 2 gastrointestinal side effects were observed in up to 50% of patients. Dose-limiting toxicity was observed in both patients treated at 350 mg/m2/d, consisting of reversible grade 2 to 3 cerebellar ataxia (n = 1) and confusion (n = 1). One minor response ...Continue Reading

Citations

Dec 21, 2000·Current Oncology Reports·T R TennantW M Stadler
Dec 1, 2001·Expert Opinion on Biological Therapy·T G Zogakis, S K Libutti
Apr 20, 2006·International Journal of Clinical Oncology·Shigeru KandaHiroshi Kanetake
May 9, 2008·International Journal of Cancer. Journal International Du Cancer·Jia-Lin YangMichael L Friedlander
Jan 10, 2008·The Journal of Pharmacology and Experimental Therapeutics·Lei GuoDechang Zhang
Dec 19, 2013·British Journal of Pharmacology·M GautierH Ouadid-Ahidouch
Oct 7, 2003·Oncogene·Apurva A DesaiMark J Ratain
May 3, 2006·Medicinal Research Reviews·Ana R QuesadaMiguel A Medina
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerMark J Ratain
Nov 30, 2004·Cancer Investigation·Benjamin Purow, Howard A Fine
Jul 5, 2005·Expert Opinion on Investigational Drugs·H T Zhang, A L Harris
Sep 13, 2019·Journal for Immunotherapy of Cancer·Jing ShiDechang Zhang
Jan 1, 1997·Critical Reviews in Biochemistry and Molecular Biology·J T PriceE C Kohn
Apr 22, 2003·Pathology Oncology Research : POR·József TímárLászló Kopper
Oct 2, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Martin FaehlingJohannes Waltenberger
Apr 13, 2000·Cancer Control : Journal of the Moffitt Cancer Center·T Mikkelsen
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mahrukh M HussainElise C Kohn
Feb 2, 2002·Current Oncology Reports·Pamela J Paley
Nov 2, 2002·The British Journal of Dermatology·P Velasco, B Lange-Asschenfeldt
Oct 19, 2007·Cancer Research·Zuben E SaunaMichael M Gottesman
Apr 12, 2008·Molecular Cancer Research : MCR·Alessandra Fiorio PlaLuca Munaron
Aug 26, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Deplanque, A L Harris
Sep 29, 2001·Drug Discovery Today·A Matter
Jan 6, 2001·Baillière's Best Practice & Research. Clinical Obstetrics & Gynaecology·M R BrownE C Kohn
Mar 1, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Terry W MoodyElise C Kohn
Jul 22, 2021·The FEBS Journal·Ling WuLiang Zhao
Nov 30, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Elizabeth A JohnsonEdith A Perez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J BerlinGeorge Wilding
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Lei GuoDe-Chang Zhang
© 2021 Meta ULC. All rights reserved